1. Adams, C. E., Fenton, M. K., Quraishi, S., & David, A. S. (2001). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry, 179(4), 290–299.
2. Babiker, I. E. (1987). Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. The Journal of Clinical Psychiatry, 48(3), 94–97.
3. Buchannan, R., Kreyenbuhl, J., Kelly, D., Noel, J., Boggs, D., Fischer, B., et al. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36(1), 71–93.
4. Dall, T. M., Wagner, A., Zhang, Y., Yang, W., Arday, D. R., & Ganatt, C. J. (2010). Outcomes and lessons learned from evaluating TRICARE’s disease management programs. The American Journal of Managed Care, 16(6), 438–446.
5. Davis, J. M., Janicak, P. G., Singla, A., & Sharma, R. P. (1993). Maintenance antipsychotic medication. In T. R. E. Barnes (Ed.), Antipsychotic drugs and their side effects (pp. 183–203). New York, NY: Academic Press.